Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bob Chen currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by a distinct examiner within a distinct art unit. The profile indicates a focus for the current patent prosecution activities. This allows for a specific and detailed response to the examiner's office action without the complexity of managing multiple cases.
JACKSON, SHAWQUIA is the busiest examiner for this portfolio, managing 1 pending office action. This examiner is responsible for the entirety of the pending workload. The outcome of the current prosecution cycle is dependent on the specific interactions with this examiner in the designated art unit. Practitioners should review the examiner's history to better understand their approach to biotechnology applications. With a distinct examiner and a distinct art unit, the prosecution strategy is centralized and focused on a technical dialogue. This ratio of actions to examiners simplifies the overall management of the patent portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 78.1% | -3.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18020317 | PROCESS FOR PREPARATION OF SUBSTITUTED PYRAZOLES | JACKSON, SHAWQUIA | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18020317 | PROCESS FOR PREPARATION OF SUBSTITUTED PYRAZOLES | JACKSON, SHAWQUIA | 1626 | §101§112 | Final Rejection | — | Pending | Feb 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBob Chen has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Shawquia Jackson has the most, with 1 of Bob Chen's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.